AsepticSure’s South American Distributor Places Order

San Francisco, California, June 20, 2016: Medizone International, Inc. (OTCQB: MZEI). GYD S.A., Medizone’s exclusive distributor for our AsepticSure® hospital disinfection system in Chile, Brazil, Colombia and Peru, intends to offer both a service model and sales model for AsepticSure distribution. They are leading the regulatory approval process in their Territory. Exclusive distribution rights will be expanded to other countries in South America on a country-by-country basis as GYD S.A. achieves regulatory approvals and establishes channels of distribution.

With regulatory approval progressing, GYD S.A. has placed an initial order for the first three Generation III AsepticSure systems. Delivery is scheduled for early July.

While the roll out of AsepticSure distribution throughout South America will be gradual, the principals of GYD S.A. have been successful twice before using the same business model in establishing distribution channels throughout the continent. Given the acute need to address major hospital based infection issues on the continent, including evidence of super bugs in Rio with the up-coming Olympic Games, the ability to greatly reduce these infection threats in the health care community is gaining attention. Medizone believes GYD S.A.’s proven business model will be successful again.

Only AsepticSure disinfection technology achieves a greater than 6-log (> 99.9999%) kill of all infective pathogensviral or bacterialthroughout the entire room. That is the same FDA standard of disinfection used to sterilize medical instruments in an autoclave. Once a room is disinfected with AsepticSure’s ‘green’ technology, it will remain safe until a new pathogen is introduced from the outside. Medizone has proven that unless 100% of infective pathogens are eliminated from the disinfected space, regrowth will occur and new infections become likely. No other disinfection technology has proven capable of eliminating the source of environmentally caused infections completely; AsepticSure does so with every room cleaning.

This Press Release may contain certain forward looking statements that could involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company’s filings made with the Securities and Exchange Commission.

For press information on Medizone International, please contact:

John Pentony, Investor and Media Relations
Medizone International, Inc.
T: 01 415 331-0202
E: j.pentony@medizoneint.com

For more information, visit:
http://www.medizoneint.com
Email: operations@medizoneint.com

AsepticSure Receives EU Patent Approval For its Bio-Terrorism Counter Measures Application

San Francisco, California, June 13, 2016 – Medizone International, Inc. (OTCQB: MZEI) is pleased to announce that its unprecedented room disinfection technology, AsepticSure®, has been granted patent protection by the European Union Patent and Trademark Office (EU) for its patent application Bio-Terrorism Counter Measures Using Ozone and Hydrogen Peroxide. The European Patent Office awarded patent number 252583B to this application, which provides a government counter measures response to a biological attack.

Medizone already has a significant number of applications granted for its disinfection technology for health care and sports facility disinfection. To date, AsepticSure has demonstrated a greater than 6-log kill (>99.9999% kill) against all bacterial and viral pathogens it has been tested against. This EU patent grant expands on the previously awarded bio-terrorism patent protection as awarded in the United States and Canada. With this EU patent, Medizone secures patent protection in the United Kingdom, Germany and France.

Recently, Acinetobacter baumannii, another highly infective pathogen of concern to certain US government interests as well as the government of South Africa, has been defeated by AsepticSure. To date, our AsepticSure technology has defeated every infective pathogen – viral or bacterial – that it has been tested against. Eliminating all infective pathogens from a disinfected space eliminates the infective reservoir, thus rendering the treated space harmless and safe.

This Press Release may contain certain forward looking statements that could involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company’s filings made with the Securities and Exchange Commission.

For press information on Medizone International, please contact:

John Pentony, Investor and Media Relations
Medizone International, Inc.
T: 01 415 331-0202
E: j.pentony@medizoneint.com

For more information, visit:
http://www.medizoneint.com
Email: operations@medizoneint.com

Medizone International, Inc. (OTCQB: MZEI)

4000 Bridgeway, Suite 401
Sausalito, CA 94965

Telephone: 415-331-0303

Email: operations@medizoneint.com

Media and Investor Relations:

John Pentony

Medizone International, Inc.

Telephone: (415) 331-0202

Email: j.pentony@medizoneint.com

Social Media


Twitter:


https://twitter.com/asepticsure

CONTACT:

Medizone International, Inc. (OTCQB: MZEI)
4000 Bridgeway, Suite 401
Sausalito, CA 94965

Telephone: 415-331-0303

Email: operations@medizoneint.com

INVESTOR & MEDIA RELATIONS:

John Pentony
Medizone International, Inc.

Telephone: (415) 331-0202E:

Email: j.pentony@medizoneint.com

SOCIAL MEDIA:

Medizone International on Twitter:

https://twitter.com/asepticsure